Latest news with #cohort
Medscape
a day ago
- Health
- Medscape
Patients With Acromegaly Face Higher Cancer Risk
TOPLINE: Patients with acromegaly had significantly higher odds of developing leukemia/lymphoma or ovarian, breast, lung, or other cancers, many of which occurred at younger ages than typically seen in the general population. These data underscored the urgent need to integrate cancer screening protocols into routine care for patients with acromegaly to facilitate earlier detection and intervention. METHODOLOGY: Excess growth hormone secretion in patients with acromegaly increases the levels of insulin-like growth factor, a known cancer risk factor; however, the true prevalence of cancer in these patients is not well known. Researchers conducted a retrospective cohort analysis using data from a multinational research network platform to compare cancer prevalence in individuals with acromegaly and those without the condition. Patients with acromegaly (n = 10,207; mean age at disease onset, 43.2 years; 52.9% women) were matched with 102,070 individuals from the general population without the condition. TAKEAWAY: Patients with acromegaly had a 3.3-fold increased odds of developing leukemia/lymphoma (95% CI, 2.3-4.67), a 1.9-fold increased odds of developing ovarian cancer (95% CI, 1.3-2.8), a 1.8-fold increased odds of developing breast cancer (95% CI, 1.5-2.0), 1.9-fold increased odds of developing lung cancer (95% CI, 1.5-2.3), and a 1.5-fold increased odds of developing prostate cancer (95% CI, 1.3-1.8). The onset of certain cancers, specifically ovarian, lung, liver, and neuroendocrine, occurred much earlier (3.2-7.2 years) in patients with acromegaly than in control individuals from the general population. IN PRACTICE: 'Our findings suggest that acromegaly may play a bigger role in cancer risk than previously thought, highlighting the need for increased awareness and early cancer screening in this population,' said the lead researcher in a press release. SOURCE: This study was led by Hitam Hagog Natour, MD, Thomas Jefferson University Hospital in Philadelphia. It was presented on July 14, 2025, at the ENDO 2025: The Endocrine Society Annual Meeting in San Francisco. LIMITATIONS: This study did not report any specific limitations. DISCLOSURES: This study did not report any specific funding or conflicts of interest. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Medscape
21-07-2025
- Health
- Medscape
C1M Biomarker May Predict Joint Damage in Early Arthritis
TOPLINE: Higher baseline serum levels of C1M, a biochemical marker of type I collagen degradation, were associated with higher odds of progression of total joint damage in patients with early arthritis at 1 and 5 years; however, the C2M marker showed no association with progression. METHODOLOGY: Researchers investigated the association between baseline serum C1M and C2M levels and the radiographic progression of joint damage in a cohort of patients with early undifferentiated inflammatory arthritis and recently developed rheumatoid arthritis (the ESPOIR cohort). They included 813 patients (mean age, 48.1 years; 76% women) having two or more swollen joints, with the swelling lasting more than 6 weeks but less than 6 months, and no previous use of disease-modifying drugs or steroids. Radiographs of the hands, wrists, and feet were obtained and scored according to the van der Heijde-modified Sharp score (mSS), assessing erosion, joint space narrowing, and total radiographic scores for each patient; serum C1M and C2M levels were assessed using biochemical assays. Radiographic progression was defined as an increase from baseline in the mSS score of at least 1 point at 1 year and of at least 5 points at 5 years. TAKEAWAY: Baseline serum levels of C1M were 42% higher in patients who had progression of total joint damage at 1 year than in those without progression (median, 68 ng/mL vs 48 ng/mL; P < .0001). Patients with baseline serum levels of C1M in the highest quartile had increased odds of progression of total joint damage (adjusted odds ratio [aOR], 2.12; P = .03) and bone erosion (aOR, 3.80; P = .005) after adjusting for the Disease Activity Score-28, C-reactive protein levels, and anti-citrullinated protein antibody positivity. Median baseline serum levels of C1M were 33% higher in patients with progression of total joint damage at 5 years than in those without progression (P = .0037); each ng/mL increase in baseline serum levels of C1M was associated with an increased risk for progression after adjusting for age, sex, and BMI (P = .016). No significant associations were found between baseline serum levels of C2M and radiologic progression at either 1 or 5 years. IN PRACTICE: "[The] biological marker [C1M] may be combined with other biomarkers of disease activity to improve the identification of patients with early arthritis at high risk for progression," the authors wrote. SOURCE: This study was led by Patrick Garnero of Inserm, Lyon, France. It was published online on July 10, 2025, in RMD Open. LIMITATIONS: At 5 years, radiologic data were available for only 60% of patients, limiting the robustness of the findings. Relationships of C1M and C2M levels with clinical progression were not analysed using the Disease Activity Score-28. Additionally, the effect of treatment groups during follow-up was not considered. DISCLOSURES: This study received an unrestricted grant from Merck Sharp and Dohme, with additional support from Inserm to support part of the biological database. The ESPOIR cohort study was supported by the French Society of Rheumatology, Pfizer, Abbvie, Lilly, Fresenius, and Biogen. One author disclosed being an employee of and owning stocks in Nordic Biosciences. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Medscape
14-07-2025
- Health
- Medscape
Lurbinectedin Shows Modest Efficacy and Safety in ES-SCLC
TOPLINE: In a multicentre study, lurbinectedin demonstrated a favourable safety profile and consistent efficacy and may be considered for compassionate use in patients with extensive-stage small cell lung cancer (ES-SCLC). However, poor performance status, a chemotherapy-free interval of less than 90 days, and the presence of brain or liver metastases may have negatively affected overall survival (OS). METHODOLOGY: This multicentric, international cohort included 238 adult patients with ES-SCLC (median age, 65 years) who received lurbinectedin intravenously at 3.2 mg/m 2 every 3 weeks as second- or further-line treatment between November 2019 and September 2024. every 3 weeks as second- or further-line treatment between November 2019 and September 2024. The primary objective was to assess the effectiveness of lurbinectedin with regard to objective response rate, disease control rate, duration of response, progression-free survival (PFS), and OS and its safety profile. The median follow-up duration was 5.53 months. TAKEAWAY: Overall, 37% of patients received lurbinectedin as second-line therapy, 45% received it as third-line therapy, and 18% received it as further-line therapy. The objective response rate was 23.1%, and the disease control rate was 45.4%. The median PFS was 2.2 months, and the median OS was 5.4 months. The 6-month PFS and OS rates were 12.2% and 42.4%, respectively. Patients with a chemotherapy-free interval of 90 days or more showed significantly longer PFS (3.1 vs 1.8 months; hazard ratio [HR], 0.46; P < .001) and OS (6.8 vs 4.5 months; HR, 0.56; P = .006) than chemoresistant patients. Eastern Cooperative Oncology Group performance status of two or more at treatment start and the presence of brain or liver metastases were associated with worse outcomes. Treatment-related adverse events (AEs) of any grade were recorded in 92% of patients, with 29% of patients experiencing at least one grade 3-4 toxicity and the most frequent being neutropenia that occurred in 22% of patients. IN PRACTICE: "Our study provides valuable real-world insights into the effectiveness and safety of lurbinectedin as compassionate use treatment for ES-SCLC, supporting its use with outcomes consistent with those observed in clinical trials and other real-world studies. However, the outcomes for patients with poor PS [performance status] at lurbinectedin start, a CFI [chemotherapy-free interval] of less than 90 days, and brain or liver metastases remain suboptimal and this should be carefully considered when making treatment decisions," the authors of the study wrote. SOURCE: This study was led by Daniela Scattolin, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy. It was published online on July 02, 2025, in the European Journal of Cancer. LIMITATIONS: This study was limited by its retrospective design, the small number of participating centres, and imbalanced cohort sizes between countries. Researchers noted heterogeneity in baseline patient characteristics, treatment management strategies, and tumour assessment protocols. Additionally, differences in national regulations regarding chemoimmunotherapy use could have introduced bias. The retrospective nature of data collection may have resulted in underreporting of AEs. DISCLOSURES: This study did not receive any specific funding. Several authors reported receiving speaker/consultant fees and having other ties with various sources. Additional disclosures are noted in the original article. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Yahoo
18-05-2025
- Sport
- Yahoo
Baseball Needs More Young Adult Fans. Here's How to Get Them.
I asked my sports-savvy daughter what the game can do to attract her and her cohort. She offered five ideas.
